These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26738757)

  • 1. Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
    van der Have M; Oldenburg B; Kaptein AA; Jansen JM; Scheffer RC; van Tuyl BA; van der Meulen-de Jong AE; Pierik M; Siersema PD; van Oijen MG; Fidder HH
    J Crohns Colitis; 2016 May; 10(5):549-55. PubMed ID: 26738757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
    Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
    Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients.
    de Jong ME; Smits LJT; van Ruijven B; den Broeder N; Russel MGVM; Römkens TEH; West RL; Jansen JM; Hoentjen F
    J Crohns Colitis; 2020 Jul; 14(7):888-895. PubMed ID: 31974546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index.
    de Castro ML; Sanromán L; Martín A; Figueira M; Martínez N; Hernández V; Del Campo V; Pineda JR; Martínez-Cadilla J; Pereira S; Rodríguez Prada JI
    Rev Esp Enferm Dig; 2017 Aug; 109(8):542-551. PubMed ID: 28679280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease.
    San EH; Egberts A; van Dijck-van Boetzelaer CWT; West RL; Vasbinder EC
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1089-1096. PubMed ID: 38553558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
    Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
    Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era.
    Campos S; Portela F; Sousa P; Sofia C
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1313-9. PubMed ID: 27501126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease.
    Mahmoud R; Schultheiss HP; Louwers J; van der Kaaij M; van Hellemondt B; Mahmmod N; van Boeckel P; Jharap B; Fidder H; Oldenburg B
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2577-2587.e6. PubMed ID: 35101632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Nugent Z; Singh H; Bernstein CN
    Inflamm Bowel Dis; 2017 Mar; 23(3):409-420. PubMed ID: 28221250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
    J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
    Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
    Bots SJA; Hoekman DR; Benninga MA; Ponsioen CY; D'Haens GR; Löwenberg M
    Neth J Med; 2017 Dec; 75(10):432-442. PubMed ID: 29256410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
    Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
    JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study.
    Fumery M; Dupont C; Ley D; Savoye G; Bertrand V; Guillon N; Wils P; Gower-Rousseau C; Sarter H; Turck D; Leroyer A
    Dig Liver Dis; 2024 Jan; 56(1):21-28. PubMed ID: 37137808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease-A Cohort Study.
    Madsen KG; Pottegård A; Hallas J; Kjeldsen J
    Inflamm Bowel Dis; 2018 Nov; 24(12):2628-2633. PubMed ID: 29788214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review.
    Lopez A; Billioud V; Peyrin-Biroulet C; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2013 Jun; 19(7):1528-33. PubMed ID: 23518810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.